- Email: [email protected]
Lung Cancer in Patients Under 40 Years: a Prospective Observational Multicenter Study (Groupe Français De Pneumo-Cancérologie (Gfpc) 1001 Study)
Annals of Oncology 25 (Supplement 4): iv542–iv545, 2014 doi:10.1093/annonc/mdu357.9
thoracic malignancies, other 1565P
Aim: Lung cancer in patients under 40 years is infrequent and few data are available about the presentation and outcomes of lung cancer in this population. This study aimed to describe the clinical characteristics, the treatments and the outcome of lung cancer occurring in the population of young adults in France. Methods: A prospective observational clinical study was conducted in 37 centers in France. All patients under 40 years diagnosed with lung cancer between November 2010 and December 2013 were enrolled. Results: One hundred and fifty nine patients with lung cancer were included. Intermediate results are currently available for 117 patients. Median age at diagnosis was 38 (20-40). The proportion of men was 58%. Median time between symptoms and diagnosis was 2 months. The distribution of stages I- II, IIIA and IIIB-IV was 9%, 9% and 82% respectively; 66% were diagnosed with metastasis at presentation and the first metastasis site was brain in 47% of patients. Adenocarcinoma was the most common histologic subtype (78%). EGFR screening was performed for 83 patients and 10% of the patients had an activating mutation. Analysis of other driver biomarkers is ongoing. Eighty-four patients (86%) were current or former tobacco smoker with a median of 20 packs -year. Sixty-nine patients (59%) have been exposed to passive smoking essentially in childhood. About half of them (46%) were current or former cannabis smoker (among which 50% regularly). Socioeconomic status was lower comparing to general population, 24% of the patients had no diploma. The first line treatments were 88% chemotherapy, 43% radiotherapy, 21% surgery and 5% best supportive care. Median overall survival was 14.7 months. Conclusions: This study is the first national prospective study dedicated to patients under 40 years diagnosed with lung cancer. Compared to the general population of lung cancer, our preliminary results show a high proportion of women, adenocarcinoma histology, advanced disease at diagnosis and tobacco and cannabis use. Final analysis will be presented at the congress. Disclosure: All authors have declared no conflicts of interest.
abstracts
L. Bigay-Gamé1, S. Bota2, L. Greillier3, I. Monnet4, A. Madroszyk5, R. Corre6, B. Mastroianni7, L. Falchero8, C. Chouaid 9, C. Audigier-Valette10, N. Baize11, C. Daniel12, G. Fraboulet13, D. Gossot14, C. Raynaud15, J. Mazières16, H. Colineaux17, B. Lepage18, G. Robinet19 1 Department of Thoracic Oncology, Hopital Larrey, CHU Toulouse, Toulouse, FRANCE 2 Pulmonology Department, CHU Rouen, Rouen, FRANCE 3 Multidisciplinary Oncology & Therapeutic Innovations, Aix-Marseille Univ, Assistance Publique-Hôpitaux de Marseille, Marseille, FRANCE 4 Pulmonology, Centre Hospitalier intercommunal de creteil, creteil, FRANCE 5 Department of Medical Oncology, Institut Paoli Calmettes, Marseille, FRANCE 6 Pulmonology Department, CHU Pontchaillou, Rennes, FRANCE 7 Pulmonology Department, CHU Lyon, Lyon, FRANCE 8 Pulmonology Department, Centre Hospitalier de Villefranche-sur-Saône, Villefranche-sur-Saône, FRANCE 9 Pneumologie, Pneumologie, APHP, Paris, FRANCE 10 Pulmonology Department, Centre Hospitalier de Toulon, Toulon, FRANCE 11 Pneumologie, C.H.U. Angers, Angers, FRANCE 12 Department of Medical Oncology, Institut Curie, Paris, FRANCE 13 Pulmonology Department, centre Hospitalier de Pontoise, Pontoise, FRANCE 14 Department of Thoracic Oncology, Institut Mutualiste Montsouris, Paris, FRANCE 15 Pulmonology Department, Centre Hospitalier d’Argenteuil, Argenteuil, FRANCE 16 Thoracic Oncology, Larrey, Toulouse University Hospital, Toulouse, FRANCE 17 Service d’Épidémiologie, CHU Toulouse, Toulouse, FRANCE 18 CICT, CHU Toulouse - CICT, Toulouse, FRANCE
Department of Medical Oncology, C.H.U. MorvanInstitut de Cancerologie et d’Hematologie, Brest, FRANCE
© European Society for Medical Oncology 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: [email protected].
Downloaded from https://academic.oup.com/annonc/article-abstract/25/suppl_4/iv544/2242257 by guest on 24 October 2019
LUNG CANCER IN PATIENTS UNDER 40 YEARS: A PROSPECTIVE OBSERVATIONAL MULTICENTER STUDY (GROUPE FRANÇAIS DE PNEUMO-CANCÉROLOGIE (GFPC) 1001 STUDY)
19
thoracic malignancies, other 1565P
Aim: Lung cancer in patients under 40 years is infrequent and few data are available about the presentation and outcomes of lung cancer in this population. This study aimed to describe the clinical characteristics, the treatments and the outcome of lung cancer occurring in the population of young adults in France. Methods: A prospective observational clinical study was conducted in 37 centers in France. All patients under 40 years diagnosed with lung cancer between November 2010 and December 2013 were enrolled. Results: One hundred and fifty nine patients with lung cancer were included. Intermediate results are currently available for 117 patients. Median age at diagnosis was 38 (20-40). The proportion of men was 58%. Median time between symptoms and diagnosis was 2 months. The distribution of stages I- II, IIIA and IIIB-IV was 9%, 9% and 82% respectively; 66% were diagnosed with metastasis at presentation and the first metastasis site was brain in 47% of patients. Adenocarcinoma was the most common histologic subtype (78%). EGFR screening was performed for 83 patients and 10% of the patients had an activating mutation. Analysis of other driver biomarkers is ongoing. Eighty-four patients (86%) were current or former tobacco smoker with a median of 20 packs -year. Sixty-nine patients (59%) have been exposed to passive smoking essentially in childhood. About half of them (46%) were current or former cannabis smoker (among which 50% regularly). Socioeconomic status was lower comparing to general population, 24% of the patients had no diploma. The first line treatments were 88% chemotherapy, 43% radiotherapy, 21% surgery and 5% best supportive care. Median overall survival was 14.7 months. Conclusions: This study is the first national prospective study dedicated to patients under 40 years diagnosed with lung cancer. Compared to the general population of lung cancer, our preliminary results show a high proportion of women, adenocarcinoma histology, advanced disease at diagnosis and tobacco and cannabis use. Final analysis will be presented at the congress. Disclosure: All authors have declared no conflicts of interest.
abstracts
L. Bigay-Gamé1, S. Bota2, L. Greillier3, I. Monnet4, A. Madroszyk5, R. Corre6, B. Mastroianni7, L. Falchero8, C. Chouaid 9, C. Audigier-Valette10, N. Baize11, C. Daniel12, G. Fraboulet13, D. Gossot14, C. Raynaud15, J. Mazières16, H. Colineaux17, B. Lepage18, G. Robinet19 1 Department of Thoracic Oncology, Hopital Larrey, CHU Toulouse, Toulouse, FRANCE 2 Pulmonology Department, CHU Rouen, Rouen, FRANCE 3 Multidisciplinary Oncology & Therapeutic Innovations, Aix-Marseille Univ, Assistance Publique-Hôpitaux de Marseille, Marseille, FRANCE 4 Pulmonology, Centre Hospitalier intercommunal de creteil, creteil, FRANCE 5 Department of Medical Oncology, Institut Paoli Calmettes, Marseille, FRANCE 6 Pulmonology Department, CHU Pontchaillou, Rennes, FRANCE 7 Pulmonology Department, CHU Lyon, Lyon, FRANCE 8 Pulmonology Department, Centre Hospitalier de Villefranche-sur-Saône, Villefranche-sur-Saône, FRANCE 9 Pneumologie, Pneumologie, APHP, Paris, FRANCE 10 Pulmonology Department, Centre Hospitalier de Toulon, Toulon, FRANCE 11 Pneumologie, C.H.U. Angers, Angers, FRANCE 12 Department of Medical Oncology, Institut Curie, Paris, FRANCE 13 Pulmonology Department, centre Hospitalier de Pontoise, Pontoise, FRANCE 14 Department of Thoracic Oncology, Institut Mutualiste Montsouris, Paris, FRANCE 15 Pulmonology Department, Centre Hospitalier d’Argenteuil, Argenteuil, FRANCE 16 Thoracic Oncology, Larrey, Toulouse University Hospital, Toulouse, FRANCE 17 Service d’Épidémiologie, CHU Toulouse, Toulouse, FRANCE 18 CICT, CHU Toulouse - CICT, Toulouse, FRANCE
Department of Medical Oncology, C.H.U. MorvanInstitut de Cancerologie et d’Hematologie, Brest, FRANCE
© European Society for Medical Oncology 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: [email protected].
Downloaded from https://academic.oup.com/annonc/article-abstract/25/suppl_4/iv544/2242257 by guest on 24 October 2019
LUNG CANCER IN PATIENTS UNDER 40 YEARS: A PROSPECTIVE OBSERVATIONAL MULTICENTER STUDY (GROUPE FRANÇAIS DE PNEUMO-CANCÉROLOGIE (GFPC) 1001 STUDY)
19